FAQ: Quantum BioPharma's Response to Law Firm Claims and Company Overview
Summary
Quantum BioPharma has formally rejected what it calls vague and unsubstantiated claims by The Schall Law Firm and DJS Law Group regarding alleged securities law violations. The company is reviewing the conduct of both firms and will take appropriate action against what it believes is a deliberate attempt to harm its reputation.
What is the main topic of this announcement?
Quantum BioPharma has issued a formal response rejecting what it describes as vague and unsubstantiated claims made by The Schall Law Firm and DJS Law Group regarding alleged securities law violations. The company states these announcements lack factual detail and appear intended to mislead investors.
Why is Quantum BioPharma responding to these law firm announcements?
The company believes the claims are unsubstantiated and appear intended to mislead investors and provoke unwarranted concern. Quantum BioPharma is reviewing the conduct of both firms and will take appropriate action to address what it believes is a deliberate attempt to harm its reputation.
What actions is Quantum BioPharma taking regarding these claims?
Quantum BioPharma is reviewing the conduct of both The Schall Law Firm and DJS Law Group and their principals. The company has stated it will take appropriate action to address what it believes is a deliberate attempt to harm its reputation.
What is Quantum BioPharma’s primary business focus?
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. The company has drug candidates in different stages of development.
What is Lucid-MS and what does it treat?
Lucid-MS is Quantum BioPharma’s lead compound developed through its subsidiary Lucid Psycheceuticals Inc. It is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
What is Quantum BioPharma’s relationship with Unbuzzd Wellness Inc.?
Quantum BioPharma invented unbuzzd(TM) and spun out its OTC version to Unbuzzd Wellness Inc. Quantum BioPharma retains ownership of 20.11% of Unbuzzd Wellness Inc. and receives royalty payments of 7% of sales until payments total $250 million, then 3% in perpetuity.
Where can investors find the latest news and updates about Quantum BioPharma?
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM. The full press release mentioned in this content can be viewed at https://ibn.fm/TsBbx.
What other business activities does Quantum BioPharma engage in?
Through its wholly owned subsidiary FSD Strategic Investments Inc., Quantum BioPharma maintains a portfolio of strategic investments representing loans secured by residential or commercial property. The company also retains 100% rights to develop similar products to unbuzzd(TM) for pharmaceutical and medical uses.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 252410